Atwood & Palmer Inc. Has $25.79 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Atwood & Palmer Inc. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 357,735 shares of the medical equipment provider’s stock after purchasing an additional 1,714 shares during the period. Hologic accounts for about 1.8% of Atwood & Palmer Inc.’s investment portfolio, making the stock its 23rd biggest holding. Atwood & Palmer Inc. owned 0.16% of Hologic worth $25,789,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. LaFleur & Godfrey LLC boosted its holdings in shares of Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider’s stock valued at $9,399,000 after buying an additional 3,655 shares during the last quarter. UMB Bank n.a. raised its position in Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 188 shares in the last quarter. Trivant Custom Portfolio Group LLC lifted its stake in Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the last quarter. Brooklyn Investment Group grew its position in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Hologic during the 4th quarter worth about $1,861,000. 94.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Down 0.3 %

NASDAQ HOLX opened at $69.73 on Tuesday. The company has a market cap of $15.74 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 2.38 and a beta of 0.97. Hologic, Inc. has a 1-year low of $68.61 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $74.65 and a 200-day moving average of $78.38.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the previous year, the firm earned $0.89 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HOLX. Leerink Partners reduced their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. William Blair restated an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.